<p>Ransom Advisory Ltd 在第一季度购买了强生（NYSE:JNJ - 免费报告）股票的新头寸，根据该公司最近向证券交易委员会（SEC）提交的文件。该公司购买了 12,197 股强生的股票，价值约为 2,023,000 美元。强生占 Ransom Advisory Ltd 投资组合的 1.0%，成为其第 24 大持仓。</p>
<ul>
<li>随着市场轮动，这只医疗保健 ETF 引领潮流</li>
</ul>
<p>其他对冲基金和机构投资者也增加或减少了对该公司的持股。先锋集团（Vanguard Group Inc.）在第一季度将其在强生的持股增加了 0.5%。先锋集团目前拥有 233,962,679 股强生的股票，价值为 38,800,371,000 美元，在上个季度又增持了 1,170,120 股。北方信托公司（Northern Trust Corp）在第一季度将其在强生的持股增加了 0.4%。北方信托公司目前拥有 30,943,820 股强生的股票，价值为 5,131,723,000 美元，在上个季度又购买了 130,645 股。纽约梅隆银行（Bank of New York Mellon Corp）在第一季度将其在强生的持股增加了 26.4%。纽约梅隆银行目前拥有 23,182,464 股强生的股票，价值为 3,844,580,000 美元，在上个季度又购买了 4,842,582 股。查尔斯·施瓦布投资管理公司（Charles Schwab Investment Management Inc.）在第一季度将其在强生的持股增加了 3.9%。查尔斯·施瓦布投资管理公司目前拥有 18,899,263 股强生的股票，价值为 3,133,602,000 美元，在上个季度又购买了 712,181 股。最后，马萨诸塞金融服务公司（Massachusetts Financial Services Co. MA）在第一季度将其在强生的持股增加了 2.5%。马萨诸塞金融服务公司目前拥有 18,282,410 股强生的股票，价值为 3,031,955,000 美元，在上个季度又购买了 448,666 股。目前 69.55% 的股票由机构投资者持有。</p>
<p>获取 <strong>强生</strong> 的提醒：</p>
<h2>分析师评级变动</h2>
<p>一些研究分析师最近对 JNJ 股票发表了评论。瑞银集团（UBS Group）将强生的目标价格从 180.00 美元上调至 190.00 美元，并在 7 月 17 日的研究报告中给予该公司 “买入” 评级。Leerink Partners 将强生的股票评级从 “跑赢大盘” 下调至 “市场表现”，并在 5 月 13 日的报告中将其目标价格从 169.00 美元下调至 153.00 美元。巴克莱（Barclays）将强生的目标价格从 165.00 美元上调至 176.00 美元，并在 7 月 17 日的研究报告中给予该公司 “持平” 评级。Leerink Partners 在 5 月 13 日的报告中将强生的评级从 “强力买入” 下调至 “持有”。最后，花旗集团（Citigroup）在 8 月 21 日的研究报告中将强生的目标价格从 185.00 美元上调至 200.00 美元，并给予该公司 “买入” 评级。两位股票研究分析师对该股票给予了强力买入评级，九位给予了买入评级，九位给予了持有评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “适度买入”，共识目标价格为 176.29 美元。</p>
<ul>
<li>JNJ 股票上涨表明对新增长路径的信心</li>
</ul>
<p><strong>阅读我们对 JNJ 的最新分析</strong></p>
<h2>强生的内部交易</h2>
<p>在其他消息中，执行副总裁 Jennifer L. Taubert 在 9 月 4 日的交易中出售了 56,471 股强生股票。该股票以 177.81 美元的平均价格出售，总价值为 10,041,108.51 美元。交易后，该执行副总裁直接持有 178,013 股公司股票，价值约为 31,652,491.53 美元。这笔交易代表了其持仓的 24.08% 的减少。该出售在向 SEC 的法律文件中披露，可以通过此超链接访问。公司内部人士持有公司股票的 0.16%。</p>
<h2>强生股票下跌 0.6%</h2>
<ul>
<li>3 个强劲盈利支撑的大型分红投资</li>
</ul>
<p>强生（NYSE:JNJ）股票在周三开盘时为 177.12 美元。该股票的 50 日移动平均价格为 169.51 美元，200 日移动平均价格为 161.02 美元。该公司的市值为 4265.7 亿美元，市盈率为 18.94，PEG 比率为 2.27，贝塔值为 0.40。强生的 52 周低点为 140.68 美元，52 周高点为 181.16 美元。该公司的债务股本比为 0.50，速动比率为 0.76，流动比率为 1.01。</p>
<p>强生（NYSE:JNJ - 获取免费报告）最近在 7 月 16 日发布了季度财报。该公司报告每股收益（EPS）为 2.77 美元，超出分析师的共识预期 2.68 美元，超出幅度为 0.09 美元。该公司在本季度的收入为 237.4 亿美元，而共识预期为 228.5 亿美元。强生的股本回报率为 32.49%，净利润率为 25.00%。该公司的收入较去年同期增长了 5.8%。在去年同期，该公司每股收益为 2.82 美元。强生已将其 2025 财年的指导目标设定为每股收益 10.800-10.900 美元。卖方分析师预计强生在当前年度的每股收益为 10.58 美元。</p>
<h2>强生分红公告</h2>
<p>该公司最近还宣布了季度分红，已于 9 月 9 日支付。8 月 26 日的股东获得了每股 1.30 美元的分红。除息日期为 8 月 26 日。这相当于每年 5.20 美元的分红，收益率为 2.9%。强生的分红支付比率目前为 55.61%。</p>
<h2>强生公司简介</h2>
<p>（免费报告）</p>
<p>强生是一家控股公司，专注于医疗保健领域的产品研究、开发、制造和销售。它通过创新药物和医疗技术两个部门运营。创新药物部门专注于免疫学、传染病、神经科学、肿瘤学、心血管和代谢以及肺动脉高压。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票，胜过强生</li>
<li>内部交易可能并不会告诉你你想的那样</li>
<li>CoreWeave 和 Madrigal 的内部交易闪现看涨信号</li>
<li>黄金交叉股票：模式、示例和图表</li>
<li>八月最被升级的：3 只目标价上调超过 20 的股票</li>
<li>什么是 MACD 指标以及如何在交易中使用它</li>
<li>高通是否是特斯拉在自动驾驶领域的下一个竞争对手？</li>
</ul>
<p><strong>想看看其他对强生持有股份的对冲基金吗？</strong> 请访问 HoldingsChannel.com 获取强生（NYSE:JNJ - 免费报告）的最新 13F 文件和内部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg"/></p>
<p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在强生吗？</h2>
<p>在你考虑强生之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而强生并不在名单上。</p>
<p>虽然强生目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

强生

<p>Ransom Advisory Ltd 在第一季度收购了 12,197 股强生（NYSE: JNJ），价值约为 2,023,000 美元，使其成为其投资组合中第 24 大持仓。其他机构投资者，包括先锋集团和北方信托，也增加了他们的持股。分析师对 JNJ 的评级意见不一，普遍评级为 “适度买入”，目标价为 176.29 美元。该股票开盘价为 177.12 美元，市值为 4265.7 亿美元，市盈率为 18.94</p>

<p>Ransom Advisory Ltd bought a new position in shares of Johnson &amp; Johnson (NYSE:JNJ - Free Report) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 12,197 shares of the company's stock, valued at approximately $2,023,000. Johnson &amp; Johnson makes up 1.0% of Ransom Advisory Ltd's investment portfolio, making the stock its 24th biggest position.</p>
<div class="lb-trans"><p>Ransom Advisory Ltd 在第一季度购买了强生（NYSE:JNJ - 免费报告）股票的新头寸，根据该公司最近向证券交易委员会（SEC）提交的文件。该公司购买了 12,197 股强生的股票，价值约为 2,023,000 美元。强生占 Ransom Advisory Ltd 投资组合的 1.0%，成为其第 24 大持仓。</p>
</div><ul>
<li>As the Market Rotates, This Healthcare ETF Is Leading the Way</li>
</ul>
<div class="lb-trans"><ul>
<li>随着市场轮动，这只医疗保健 ETF 引领潮流</li>
</ul>
</div><p>Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. grew its stake in Johnson &amp; Johnson by 0.5% during the first quarter. Vanguard Group Inc. now owns 233,962,679 shares of the company's stock valued at $38,800,371,000 after acquiring an additional 1,170,120 shares in the last quarter. Northern Trust Corp increased its holdings in shares of Johnson &amp; Johnson by 0.4% in the first quarter. Northern Trust Corp now owns 30,943,820 shares of the company's stock worth $5,131,723,000 after purchasing an additional 130,645 shares during the last quarter. Bank of New York Mellon Corp lifted its position in shares of Johnson &amp; Johnson by 26.4% in the first quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company's stock worth $3,844,580,000 after buying an additional 4,842,582 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Johnson &amp; Johnson by 3.9% during the first quarter. Charles Schwab Investment Management Inc. now owns 18,899,263 shares of the company's stock valued at $3,133,602,000 after buying an additional 712,181 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA grew its holdings in Johnson &amp; Johnson by 2.5% during the 1st quarter. Massachusetts Financial Services Co. MA now owns 18,282,410 shares of the company's stock valued at $3,031,955,000 after buying an additional 448,666 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>其他对冲基金和机构投资者也增加或减少了对该公司的持股。先锋集团（Vanguard Group Inc.）在第一季度将其在强生的持股增加了 0.5%。先锋集团目前拥有 233,962,679 股强生的股票，价值为 38,800,371,000 美元，在上个季度又增持了 1,170,120 股。北方信托公司（Northern Trust Corp）在第一季度将其在强生的持股增加了 0.4%。北方信托公司目前拥有 30,943,820 股强生的股票，价值为 5,131,723,000 美元，在上个季度又购买了 130,645 股。纽约梅隆银行（Bank of New York Mellon Corp）在第一季度将其在强生的持股增加了 26.4%。纽约梅隆银行目前拥有 23,182,464 股强生的股票，价值为 3,844,580,000 美元，在上个季度又购买了 4,842,582 股。查尔斯·施瓦布投资管理公司（Charles Schwab Investment Management Inc.）在第一季度将其在强生的持股增加了 3.9%。查尔斯·施瓦布投资管理公司目前拥有 18,899,263 股强生的股票，价值为 3,133,602,000 美元，在上个季度又购买了 712,181 股。最后，马萨诸塞金融服务公司（Massachusetts Financial Services Co. MA）在第一季度将其在强生的持股增加了 2.5%。马萨诸塞金融服务公司目前拥有 18,282,410 股强生的股票，价值为 3,031,955,000 美元，在上个季度又购买了 448,666 股。目前 69.55% 的股票由机构投资者持有。</p>
</div><p>Get <strong>Johnson &amp; Johnson</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>强生</strong> 的提醒：</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>A number of research analysts have recently commented on JNJ shares. UBS Group increased their target price on Johnson &amp; Johnson from $180.00 to $190.00 and gave the company a &#34;buy&#34; rating in a research report on Thursday, July 17th. Leerink Partners downgraded shares of Johnson &amp; Johnson from an &#34;outperform&#34; rating to a &#34;market perform&#34; rating and reduced their target price for the stock from $169.00 to $153.00 in a report on Tuesday, May 13th. Barclays raised their price objective on Johnson &amp; Johnson from $165.00 to $176.00 and gave the company an &#34;equal weight&#34; rating in a research note on Thursday, July 17th. Leerink Partnrs lowered Johnson &amp; Johnson from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Tuesday, May 13th. Finally, Citigroup boosted their price objective on shares of Johnson &amp; Johnson from $185.00 to $200.00 and gave the company a &#34;buy&#34; rating in a research report on Thursday, August 21st. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and nine have assigned a Hold rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $176.29.</p>
<div class="lb-trans"><p>一些研究分析师最近对 JNJ 股票发表了评论。瑞银集团（UBS Group）将强生的目标价格从 180.00 美元上调至 190.00 美元，并在 7 月 17 日的研究报告中给予该公司 “买入” 评级。Leerink Partners 将强生的股票评级从 “跑赢大盘” 下调至 “市场表现”，并在 5 月 13 日的报告中将其目标价格从 169.00 美元下调至 153.00 美元。巴克莱（Barclays）将强生的目标价格从 165.00 美元上调至 176.00 美元，并在 7 月 17 日的研究报告中给予该公司 “持平” 评级。Leerink Partners 在 5 月 13 日的报告中将强生的评级从 “强力买入” 下调至 “持有”。最后，花旗集团（Citigroup）在 8 月 21 日的研究报告中将强生的目标价格从 185.00 美元上调至 200.00 美元，并给予该公司 “买入” 评级。两位股票研究分析师对该股票给予了强力买入评级，九位给予了买入评级，九位给予了持有评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “适度买入”，共识目标价格为 176.29 美元。</p>
</div><ul>
<li>JNJ Stock Surge Signals Confidence in New Growth Path</li>
</ul>
<div class="lb-trans"><ul>
<li>JNJ 股票上涨表明对新增长路径的信心</li>
</ul>
</div><p><strong>Read Our Latest Analysis on JNJ</strong></p>
<div class="lb-trans"><p><strong>阅读我们对 JNJ 的最新分析</strong></p>
</div><h2>Insider Transactions at Johnson &amp; Johnson</h2>
<div class="lb-trans"><h2>强生的内部交易</h2>
</div><p>In other news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson &amp; Johnson stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 0.16% of the company's stock.</p>
<div class="lb-trans"><p>在其他消息中，执行副总裁 Jennifer L. Taubert 在 9 月 4 日的交易中出售了 56,471 股强生股票。该股票以 177.81 美元的平均价格出售，总价值为 10,041,108.51 美元。交易后，该执行副总裁直接持有 178,013 股公司股票，价值约为 31,652,491.53 美元。这笔交易代表了其持仓的 24.08% 的减少。该出售在向 SEC 的法律文件中披露，可以通过此超链接访问。公司内部人士持有公司股票的 0.16%。</p>
</div><h2>Johnson &amp; Johnson Stock Down 0.6%</h2>
<div class="lb-trans"><h2>强生股票下跌 0.6%</h2>
</div><ul>
<li>3 Big Dividend Plays With Strong Earnings to Back Them</li>
</ul>
<div class="lb-trans"><ul>
<li>3 个强劲盈利支撑的大型分红投资</li>
</ul>
</div><p>Shares of NYSE JNJ opened at $177.12 on Wednesday. The stock has a 50 day moving average price of $169.51 and a 200 day moving average price of $161.02. The firm has a market capitalization of $426.57 billion, a price-to-earnings ratio of 18.94, a PEG ratio of 2.27 and a beta of 0.40. Johnson &amp; Johnson has a 52-week low of $140.68 and a 52-week high of $181.16. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01.</p>
<div class="lb-trans"><p>强生（NYSE:JNJ）股票在周三开盘时为 177.12 美元。该股票的 50 日移动平均价格为 169.51 美元，200 日移动平均价格为 161.02 美元。该公司的市值为 4265.7 亿美元，市盈率为 18.94，PEG 比率为 2.27，贝塔值为 0.40。强生的 52 周低点为 140.68 美元，52 周高点为 181.16 美元。该公司的债务股本比为 0.50，速动比率为 0.76，流动比率为 1.01。</p>
</div><p>Johnson &amp; Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.68 by $0.09. The business had revenue of $23.74 billion for the quarter, compared to the consensus estimate of $22.85 billion. Johnson &amp; Johnson had a return on equity of 32.49% and a net margin of 25.00%.The business's revenue was up 5.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.82 EPS. Johnson &amp; Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Sell-side analysts expect that Johnson &amp; Johnson will post 10.58 earnings per share for the current year.</p>
<div class="lb-trans"><p>强生（NYSE:JNJ - 获取免费报告）最近在 7 月 16 日发布了季度财报。该公司报告每股收益（EPS）为 2.77 美元，超出分析师的共识预期 2.68 美元，超出幅度为 0.09 美元。该公司在本季度的收入为 237.4 亿美元，而共识预期为 228.5 亿美元。强生的股本回报率为 32.49%，净利润率为 25.00%。该公司的收入较去年同期增长了 5.8%。在去年同期，该公司每股收益为 2.82 美元。强生已将其 2025 财年的指导目标设定为每股收益 10.800-10.900 美元。卖方分析师预计强生在当前年度的每股收益为 10.58 美元。</p>
</div><h2>Johnson &amp; Johnson Dividend Announcement</h2>
<div class="lb-trans"><h2>强生分红公告</h2>
</div><p>The business also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were issued a dividend of $1.30 per share. The ex-dividend date was Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a yield of 2.9%. Johnson &amp; Johnson's dividend payout ratio is currently 55.61%.</p>
<div class="lb-trans"><p>该公司最近还宣布了季度分红，已于 9 月 9 日支付。8 月 26 日的股东获得了每股 1.30 美元的分红。除息日期为 8 月 26 日。这相当于每年 5.20 美元的分红，收益率为 2.9%。强生的分红支付比率目前为 55.61%。</p>
</div><h2>Johnson &amp; Johnson Company Profile</h2>
<div class="lb-trans"><h2>强生公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Johnson &amp; Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.</p>
<div class="lb-trans"><p>强生是一家控股公司，专注于医疗保健领域的产品研究、开发、制造和销售。它通过创新药物和医疗技术两个部门运营。创新药物部门专注于免疫学、传染病、神经科学、肿瘤学、心血管和代谢以及肺动脉高压。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Johnson &amp; Johnson</li>
<li>Insider Trades May Not Tell You What You Think</li>
<li>CoreWeave and Madrigal's Insider Trades Flash Bullish Signals</li>
<li>Golden Cross Stocks: Pattern, Examples and Charts</li>
<li>August's Most Upgraded: 3 Stocks With +20 Price Target Increases</li>
<li>What is the MACD Indicator and How to Use it in Your Trading</li>
<li>Is Qualcomm Tesla’s Next Rival in Autonomous Driving?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过强生</li>
<li>内部交易可能并不会告诉你你想的那样</li>
<li>CoreWeave 和 Madrigal 的内部交易闪现看涨信号</li>
<li>黄金交叉股票：模式、示例和图表</li>
<li>八月最被升级的：3 只目标价上调超过 20 的股票</li>
<li>什么是 MACD 指标以及如何在交易中使用它</li>
<li>高通是否是特斯拉在自动驾驶领域的下一个竞争对手？</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding JNJ?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson &amp; Johnson (NYSE:JNJ - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对强生持有股份的对冲基金吗？</strong> 请访问 HoldingsChannel.com 获取强生（NYSE:JNJ - 免费报告）的最新 13F 文件和内部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=JNJ"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Johnson &amp; Johnson Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在强生吗？</h2>
</div><p>Before you consider Johnson &amp; Johnson, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑强生之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson &amp; Johnson wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而强生并不在名单上。</p>
</div><p>While Johnson &amp; Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然强生目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Ransom Advisory Ltd 购买了 12,197 股强生公司（Johnson & Johnson）的股票